REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.65
+0.29 (3.10%)
At close: Sep 26, 2025, 4:00 PM EDT
9.62
-0.03 (-0.31%)
After-hours: Sep 26, 2025, 6:58 PM EDT
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$441,309
Profits / Employee
-$497,368
Market Cap
487.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 18 days ago - Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome - Seeking Alpha
- 19 days ago - REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome - Seeking Alpha
- 22 days ago - REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II - PRNewsWire
- 4 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
- 5 weeks ago - REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II - PRNewsWire
- 7 weeks ago - REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript - Seeking Alpha